An Open-Label Pharmacokinetic and Safety Study of MDX-010 in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma.
Phase of Trial: Phase I
Latest Information Update: 05 Feb 2010
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Medarex
- 05 Feb 2010 Bristol-Myers Squibb added as trial sponsor as reported by ClinicalTrials.gov.
- 28 Aug 2008 New trial record.